Medical/Pharmaceuticals
Ivonescimab Receives NMPA Priority Review for First-Line Biliary Tract Cancer
HONG KONG, Nov. 4, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) today announced that ivonescimab in combination with chemotherapy for the first-line treatment of locally advanced or metastatic biliary tract cancer (BTC) has been granted Priority Review by China's National Medical Products Adm...
2026-11-05 12:19
2818
NCCN and Viet Nam National Cancer Hospital Expand Collaboration to Advance Cancer Care Resources in Vietnam
NCCN and Viet Nam National Cancer Hospital sign agreement to enhance ongoing guideline adaptation efforts with the inclusion of additional hematologic and solid tumor information. HANOI, Vietnam, Nov. 5, 2026 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) today announced the...
2026-11-05 10:06
4243
ONE OF THE WORLD'S FIRST PERSONALISED BRAIN STIMULATION STUDIES SHOWS PROMISE FOR SEVERE OCD WITH NUH AND NUS MEDICINE EXTENDING THE APPROACH TO DEPRESSION AND ANXIETY
Building on an established NUH–NUS Medicine collaboration, the work combines clinical expertise and cutting‑edge neuroimaging to improve outcomes for patients who have not responded to standard treatments SINGAPORE, Nov. 4, 2026 /PRNewswire/ -- Mental health treatments such as transcranial magne...
2026-11-05 08:05
2229
Illumina selected to help bring precision medicine into everyday healthcare in Singapore
SG-INSIGHT study will extend whole-genome sequencing to nearly 1 in 10 Singapore residents, generating evidence to inform how precision medicine could be implemented in Singapore's healthcare system SINGAPORE, Nov. 5, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) announced it has been selec...
2026-11-05 07:00
2229
Menarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual Meeting
* First clinical data for dapolsertib monotherapy: initial results from the Phase II JASPIS-01 study of dapolsertib (MEN1703), a first-in-class oral dual PIM/FLT3 kinase inhibitor, in patients with relapsed/refractory (r/r) aggressive B-cell non-Hodgkin lymphoma (B-NHL) who have exhausted avail...
2026-11-05 02:31
3771
Lunit Presents AI-Powered Pathology Research in Ovarian and Bladder Cancers at SITC 2026
Studies with Labcorp and CellCarta identify proliferation-related tissue differences in HRD ovarian cancer and explore spatial immune features associated with immunotherapy response in bladder cancer SEOUL, South Korea, Nov. 4, 2026 /PRNewswire/ -- Lunit (KRX: 328130), a leading provider of AI f...
2026-11-04 22:00
3175
A New Paradigm for Long-Term Weight Management: Once-Monthly Bofanglutide Maintenance Therapy Delivers Positive Results in Weight Control and Maintenance Over 24 Weeks -- Gan & Lee Pharmaceuticals' GRADUAL-3 Study Meets Its Primary Endpoint
BEIJING and BRIDGEWATER, Mass., Nov. 4, 2026 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Stock Code: 603087. SH) announced positive topline results from GRADUAL-3, a Phase III clinical study evaluating once-monthly administration of its independently developed glucagon-like peptide-1 receptor ago...
2026-11-04 21:00
11169
Crystal Pharmatech Completes ELDICO ED-1 Installation; Dedicated MicroED Now in Routine Service
Instrument operational at the Suzhou R&D center, with MicroED built into solid-form screening and results in as little as 48 hours SUZHOU, China, Nov. 4, 2026 /PRNewswire/ -- Crystal Pharmatech, a science-driven CRO/CDMO specializing in solid-state research, preformulation studies, and formulati...
2026-11-04 20:15
1697
TJ Biopharma Announces Publication of Plonmarlimab Phase 2 Results in the Journal of Hematology & Oncology
* Findings build on TJ Biopharma's pioneering work on GM-CSF as a therapeutic target in macrophage- and myeloid cell-driven inflammation * Phase 2 results show encouraging clinical responses and glucocorticoid-sparing potential in macrophage activation syndrome HANGZHOU, China, Nov. 4, 2026 /...
2026-11-04 18:00
2879
Minghui Pharmaceutical and ASKA Pharmaceutical Enter into Exclusive License Agreement for the IGF-1R Antibody in Japan
HANGZHOU, China, SHANGHAI and TOKYO, Nov. 4, 2026 /PRNewswire/ -- Minghui Pharmaceutical ("Minghui") and ASKA PharmaceuticalCo., Ltd. ("ASKA") today announced that they have entered into an exclusive license agreement for the development and commercialization of MHB018A in Japan. MHB018A is a no...
2026-11-04 14:30
3178
IASO Bio Hosts FUCASO Singapore Launch Event, Marking the Official Commercial Landing of China's Original Fully Human BCMA CAR-T Cell Therapy in Southeast Asia's Healthcare Hub
IASO Bio and its Singapore partner Pills and Pokes jointly hosted the FUCASO launch event in Singapore on November 3, marking the official commercial arrival of the world's first fully human BCMA-targeted CAR-T cell therapy in Singapore. FUCASO was approved by Singapore's Health Sciences Authorit...
2026-11-04 12:59
3095
WuXi Biologics Receives Double Honors at 2026 HERA for ESG Reporting and Environmental Excellence
HONG KONG, Nov. 3, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced it received two Grand Awards at the ninth Hong Kong ESG Reporting Awards (HERA), winning Best ESG Report (Large-Cap) and Excell...
2026-11-04 12:44
2102
Biocon Malaysia Recognised Across Five Categories at MOPI Pharma Industry Awards 2026
JOHOR BAHRU, Malaysia, Nov. 4, 2026 /PRNewswire/ -- Biocon Sdn. Bhd., Malaysia (Biocon Malaysia),a stepdown subsidiary of global biopharmaceuticals company Biocon Limited, has been recognised across five categories at the second edition of Malaysian Organisation of Pharmaceutical Industries' (MOP...
2026-11-04 11:15
2606
Samsung Biologics Achieves 'Negligible Risk' Rating in Sustainalytics ESG Assessment
* Earns ESG Risk Rating score of 9.0, ranking among the top 0.5% in the pharmaceuticals industry * Advances from 'Low Risk' to 'Negligible Risk,' the lowest ESG risk category * Recognition reflects continued improvements in ESG risk management across operations INCHEON, South Korea, Nov. 3, ...
2026-11-04 07:30
2651
Zuellig Pharma Strengthens Clinical Sourcing Capabilities in China through Strategic Acquisition
The acquisition of our newly licensed Hangzhou facility establishes robust local sourcing capabilities to accelerate and support clinical trials across China HANGZHOU, China, Nov. 3, 2026 /PRNewswire/ -- Zuellig Pharma, a leading healthcare solutions company in Asia, announced the strategic acqu...
2026-11-04 07:00
2070
Zuellig Pharma Strengthens Clinical Sourcing Capabilities in China through Strategic Acquisition
The acquisition of our newly licensed Hangzhou facility establishes robust local sourcing capabilities to accelerate and support clinical trials across China HANGZHOU, China, Nov. 4, 2026 /PRNewswire/ -- Zuellig Pharma, a leading healthcare solutions company in Asia, announced the strategic acqu...
2026-11-04 07:00
2120
MoleculeMind's New MMDesign Technical Report Demonstrates 94.7% Campaign Success Rate Across Diverse Molecular Targets and Modalities
SHANGHAI, Nov. 3, 2026 /PRNewswire/ -- MoleculeMind
2026-11-03 23:00
6030
LIPSIA-STRATEGY trial demonstrates non-inferiority of CAAS vFFR guided revascularization against pressure wire-based FFR revascularization
* LIPSIA-STRATEGY evaluated whether revascularization guided by angiography-based FFR using CAAS vFFR (vessel Fractional Flow Reserve), delivers clinical outcomes comparable to guidance by pressure wire-based FFR. * Conclusive trial results provide further randomized clinical evidence validat...
2026-11-03 19:05
2643
SIRONA 3-Year Results: Sirolimus-Coated Balloon Shows Higher Freedom From Repeat Revascularization Than Paclitaxel-Coated Balloons in Femoropopliteal Disease
Late-breaking data presented at TCT 2026
2026-11-03 18:39
2460
140th Canton Fair Phase 3 Highlights Intelligent Healthcare Innovations for a Better Life
GUANGZHOU, China, Nov. 3, 2026 /PRNewswire/ -- Phase 3 of the 140th Canton Fair, held from October 31 to November 4, centers on the theme "Better Life." As health remains central to high quality of life, the Intelligent Healthcare Zone has emerged as a focal point for buyers seeking solutions tha...
2026-11-03 14:29
3554
Week's Top Stories
Most Reposted
TD Brings its Global Asset Management Businesses Under One Name
[Picked up by 1169 media titles]
2026-11-02 20:00OceanaGold Reports Third Quarter 2026 Results
[Picked up by 1130 media titles]
2026-11-05 06:52Algolia Powers Orange with AI Agents for Billing Support: NYSE Content Update
[Picked up by 1118 media titles]
2026-11-06 22:06
Overstory Launches Integrated AI Platform to Deliver First Living Model of Grid Risk
[Picked up by 1082 media titles]
2026-11-03 22:00NYSE Chair Sharon Bowen Earns Lifetime Achievement Award: NYSE Content Update
[Picked up by 1073 media titles]
2026-11-05 22:05
Most Read
Airbrush Upgrades AI Image Enhancer With 16K Output and Batch Processing for Up to 50 Images
2026-11-03 02:00
63442
Korean Derma Skincare Brand MDP+ Launches at Nordstrom
2026-11-03 00:30
28648
Home Companion Robot Mobo to Debut Globally and Open Pre-orders as AiMOGA Showcases Its Robot Family at the 2026 OMODA & JAECOO International User Summit
2026-11-07 13:49
22680
Lorikeet Dreamweaver enables businesses to give every customer an AI account manager
2026-11-04 22:00
19583